TargetDelta-type opioid receptor(Rattus norvegicus (rat))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 0.110nMAssay Description:Binding affinity for delta opioid receptor of rat brainMore data for this Ligand-Target Pair
TargetMu-type opioid receptor(Rattus norvegicus (rat))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 0.160nMAssay Description:Binding affinity for Mu opioid receptor of rat brainMore data for this Ligand-Target Pair
TargetDelta-type opioid receptor(Rattus norvegicus (rat))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 0.300nMAssay Description:Binding affinity for delta opioid receptor of rat brainMore data for this Ligand-Target Pair
TargetDelta-type opioid receptor(Rattus norvegicus (rat))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 0.300nMAssay Description:Binding affinity for delta opioid receptor of rat brainMore data for this Ligand-Target Pair
TargetDelta-type opioid receptor(Rattus norvegicus (rat))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 0.900nMAssay Description:Binding affinity for delta opioid receptor of rat brainMore data for this Ligand-Target Pair
TargetMu-type opioid receptor(Rattus norvegicus (rat))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 1.5nMAssay Description:Binding affinity for Mu opioid receptor of rat brainMore data for this Ligand-Target Pair
TargetDelta-type opioid receptor(Rattus norvegicus (rat))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 5.20nMAssay Description:Binding affinity for delta opioid receptor of rat brainMore data for this Ligand-Target Pair
TargetMu-type opioid receptor(Rattus norvegicus (rat))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 12nMAssay Description:Binding affinity for Mu opioid receptor of rat brainMore data for this Ligand-Target Pair
TargetDelta-type opioid receptor(Rattus norvegicus (rat))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 15.1nMAssay Description:Binding affinity for delta opioid receptor of rat brainMore data for this Ligand-Target Pair
TargetDelta-type opioid receptor(Rattus norvegicus (rat))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 15.1nMAssay Description:Binding affinity for delta opioid receptor of rat brainMore data for this Ligand-Target Pair
TargetMu-type opioid receptor(Rattus norvegicus (rat))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 20.7nMAssay Description:Binding affinity for Mu opioid receptor of rat brainMore data for this Ligand-Target Pair
TargetMu-type opioid receptor(Rattus norvegicus (rat))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 20.7nMAssay Description:Binding affinity for Mu opioid receptor of rat brainMore data for this Ligand-Target Pair
TargetDelta-type opioid receptor(Rattus norvegicus (rat))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 22nMAssay Description:Binding affinity for delta opioid receptor of rat brainMore data for this Ligand-Target Pair
TargetMu-type opioid receptor(Rattus norvegicus (rat))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 23nMAssay Description:Binding affinity for Mu opioid receptor of rat brainMore data for this Ligand-Target Pair
TargetDelta-type opioid receptor(Rattus norvegicus (rat))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 50nMAssay Description:Binding affinity for delta opioid receptor of rat brainMore data for this Ligand-Target Pair
TargetMu-type opioid receptor(Rattus norvegicus (rat))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 55nMAssay Description:Binding affinity for Mu opioid receptor of rat brainMore data for this Ligand-Target Pair
TargetMu-type opioid receptor(Rattus norvegicus (rat))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 69nMAssay Description:Binding affinity for Mu opioid receptor of rat brainMore data for this Ligand-Target Pair
TargetDelta-type opioid receptor(Rattus norvegicus (rat))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: >100nMAssay Description:Binding affinity for delta opioid receptor of rat brainMore data for this Ligand-Target Pair
TargetDelta-type opioid receptor(Rattus norvegicus (rat))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: >100nMAssay Description:Binding affinity for delta opioid receptor of rat brainMore data for this Ligand-Target Pair
TargetMu-type opioid receptor(Rattus norvegicus (rat))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: >100nMAssay Description:Binding affinity for Mu opioid receptor of rat brainMore data for this Ligand-Target Pair
TargetMu-type opioid receptor(Rattus norvegicus (rat))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: >100nMAssay Description:Binding affinity for Mu opioid receptor of rat brainMore data for this Ligand-Target Pair
TargetMu-type opioid receptor(Rattus norvegicus (rat))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: >100nMAssay Description:Binding affinity for Mu opioid receptor of rat brainMore data for this Ligand-Target Pair
TargetMu-type opioid receptor(Rattus norvegicus (rat))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: >100nMAssay Description:Binding affinity for Mu opioid receptor of rat brainMore data for this Ligand-Target Pair
TargetDelta-type opioid receptor(Rattus norvegicus (rat))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: >100nMAssay Description:Binding affinity for delta opioid receptor of rat brainMore data for this Ligand-Target Pair
TargetMu-type opioid receptor(Rattus norvegicus (rat))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: >100nMAssay Description:Binding affinity for Mu opioid receptor of rat brainMore data for this Ligand-Target Pair
TargetDelta-type opioid receptor(Rattus norvegicus (rat))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: >100nMAssay Description:Binding affinity for delta opioid receptor of rat brainMore data for this Ligand-Target Pair
TargetKappa-type opioid receptor(Cavia porcellus (domestic guinea pig))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 124nMAssay Description:Binding affinity for kappa opioid receptor of guinea pig cerebellumMore data for this Ligand-Target Pair
TargetProkineticin receptor 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 19nMAssay Description:Antagonist activity at human PKR1 expressed in HEK293 cells assessed as inhibition of PK1-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
TargetProkineticin receptor 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 21nMAssay Description:Antagonist activity at human PKR1 expressed in HEK293 cells assessed as inhibition of PK1-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
TargetProkineticin receptor 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 22nMAssay Description:Antagonist activity at human PKR1 expressed in HEK293 cells assessed as inhibition of PK1-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
TargetProkineticin receptor 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 27nMAssay Description:Antagonist activity at human PKR1 expressed in HEK293 cells assessed as inhibition of PK1-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
TargetProkineticin receptor 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 33nMAssay Description:Antagonist activity at human PKR1 expressed in HEK293 cells assessed as inhibition of PK1-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
TargetProkineticin receptor 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 47nMAssay Description:Antagonist activity at human PKR1 expressed in HEK293 cells assessed as inhibition of PK1-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
TargetProkineticin receptor 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 51nMAssay Description:Antagonist activity at human PKR1 expressed in HEK293 cells assessed as inhibition of PK1-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
TargetProkineticin receptor 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 318nMAssay Description:Antagonist activity at human PKR1 expressed in HEK293 cells assessed as inhibition of PK1-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
TargetProkineticin receptor 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 336nMAssay Description:Antagonist activity at human PKR1 expressed in HEK293 cells assessed as inhibition of PK1-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
TargetProkineticin receptor 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 461nMAssay Description:Antagonist activity at human PKR1 expressed in HEK293 cells assessed as inhibition of PK1-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
TargetProkineticin receptor 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 515nMAssay Description:Antagonist activity at human PKR1 expressed in HEK293 cells assessed as inhibition of PK1-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
TargetProkineticin receptor 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 1.16E+3nMAssay Description:Antagonist activity at human PKR1 expressed in HEK293 cells assessed as inhibition of PK1-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
TargetProkineticin receptor 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 1.21E+3nMAssay Description:Antagonist activity at human PKR1 expressed in HEK293 cells assessed as inhibition of PK1-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
TargetProkineticin receptor 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 1.87E+3nMAssay Description:Antagonist activity at human PKR1 expressed in HEK293 cells assessed as inhibition of PK1-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
TargetProkineticin receptor 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 2.18E+3nMAssay Description:Antagonist activity at human PKR1 expressed in HEK293 cells assessed as inhibition of PK1-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
TargetProkineticin receptor 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 2.50E+3nMAssay Description:Antagonist activity at human PKR1 expressed in HEK293 cells assessed as inhibition of PK1-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
TargetProkineticin receptor 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 2.59E+3nMAssay Description:Antagonist activity at human PKR1 expressed in HEK293 cells assessed as inhibition of PK1-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
TargetProkineticin receptor 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 2.86E+3nMAssay Description:Antagonist activity at human PKR1 expressed in HEK293 cells assessed as inhibition of PK1-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
TargetProkineticin receptor 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 3.26E+3nMAssay Description:Antagonist activity at human PKR1 expressed in HEK293 cells assessed as inhibition of PK1-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
TargetProkineticin receptor 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 3.69E+3nMAssay Description:Antagonist activity at human PKR1 expressed in HEK293 cells assessed as inhibition of PK1-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
TargetProkineticin receptor 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 4.78E+3nMAssay Description:Antagonist activity at human PKR1 expressed in HEK293 cells assessed as inhibition of PK1-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
TargetProkineticin receptor 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 6.51E+3nMAssay Description:Antagonist activity at human PKR1 expressed in HEK293 cells assessed as inhibition of PK1-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
TargetProkineticin receptor 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: >1.00E+4nMAssay Description:Antagonist activity at human PKR1 expressed in HEK293 cells assessed as inhibition of PK1-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair